Switch theme
Sign up to access all valuation multiples
Shanghai Haohai Biological Technology Co Ltd is engaged in the manufacturing and sale of biologicals, medical hyaluronate, and ophthalmology products. The Company's operating activities are related to a single operating segment, which is the manufacture and sale of biologicals, medical hyaluronate, and intraocular lenses, research and development of biological engineering and pharmaceutical products, and the provision of related services. Its products are categorized into four types, comprising ophthalmology, medical aesthetics, orthopedics, and anti-adhesion. Geographically, it has operations in Mainland China, which is the key revenue driver, the United States, the United Kingdom, and other countries.
2007
2.2K+
LTM Revenue $428M
LTM EBITDA $99.4M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Haohai Biological has a last 12-month revenue (LTM) of $428M and a last 12-month EBITDA of $99.4M.
In the most recent fiscal year, Haohai Biological achieved revenue of $342M and an EBITDA of $88.0M.
Haohai Biological expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Haohai Biological valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $428M | XXX | $342M | XXX | XXX | XXX |
| Gross Profit | $299M | XXX | $239M | XXX | XXX | XXX |
| Gross Margin | 70% | XXX | 70% | XXX | XXX | XXX |
| EBITDA | $99.4M | XXX | $88.0M | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBIT | $80.9M | XXX | $56.9M | XXX | XXX | XXX |
| EBIT Margin | 19% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $67.2M | XXX | $53.7M | XXX | XXX | XXX |
| Net Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Haohai Biological's stock price is HKD 52 (or $7).
Haohai Biological has current market cap of HKD 11.8B (or $1.5B), and EV of HKD 9.3B (or $1.2B).
See Haohai Biological trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.5B | XXX | XXX | XXX | XXX | $0.26 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Haohai Biological has market cap of $1.5B and EV of $1.2B.
Haohai Biological's trades at 3.5x EV/Revenue multiple, and 13.5x EV/EBITDA.
Equity research analysts estimate Haohai Biological's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Haohai Biological has a P/E ratio of 24.4x.
See valuation multiples for Haohai Biological and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 3.0x | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | 13.0x | XXX | 13.5x | XXX | XXX | XXX |
| EV/EBIT | 16.0x | XXX | 20.9x | XXX | XXX | XXX |
| EV/Gross Profit | 4.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | 24.4x | XXX | 28.1x | XXX | XXX | XXX |
| EV/FCF | 26.5x | XXX | 33.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialHaohai Biological's last 12 month revenue growth is 16%
Haohai Biological's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Haohai Biological's rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Haohai Biological's rule of X is 63% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Haohai Biological and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 16% | XXX | 20% | XXX | XXX | XXX |
| EBITDA Margin | 23% | XXX | 26% | XXX | XXX | XXX |
| EBITDA Growth | 19% | XXX | 6% | XXX | XXX | XXX |
| Rule of 40 | 43% | XXX | 42% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 63% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 29% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 53% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Haohai Biological acquired XXX companies to date.
Last acquisition by Haohai Biological was XXXXXXXX, XXXXX XXXXX XXXXXX . Haohai Biological acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Haohai Biological founded? | Haohai Biological was founded in 2007. |
| Where is Haohai Biological headquartered? | Haohai Biological is headquartered in Hong Kong. |
| How many employees does Haohai Biological have? | As of today, Haohai Biological has 2.2K+ employees. |
| Is Haohai Biological publicy listed? | Yes, Haohai Biological is a public company listed on HKG. |
| What is the stock symbol of Haohai Biological? | Haohai Biological trades under 06826 ticker. |
| When did Haohai Biological go public? | Haohai Biological went public in 2015. |
| Who are competitors of Haohai Biological? | Similar companies to Haohai Biological include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Haohai Biological? | Haohai Biological's current market cap is $1.5B |
| What is the current revenue of Haohai Biological? | Haohai Biological's last 12 months revenue is $428M. |
| What is the current revenue growth of Haohai Biological? | Haohai Biological revenue growth (NTM/LTM) is 16%. |
| What is the current EV/Revenue multiple of Haohai Biological? | Current revenue multiple of Haohai Biological is 3.0x. |
| Is Haohai Biological profitable? | Yes, Haohai Biological is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Haohai Biological? | Haohai Biological's last 12 months EBITDA is $99.4M. |
| What is Haohai Biological's EBITDA margin? | Haohai Biological's last 12 months EBITDA margin is 23%. |
| What is the current EV/EBITDA multiple of Haohai Biological? | Current EBITDA multiple of Haohai Biological is 13.0x. |
| What is the current FCF of Haohai Biological? | Haohai Biological's last 12 months FCF is $48.8M. |
| What is Haohai Biological's FCF margin? | Haohai Biological's last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Haohai Biological? | Current FCF multiple of Haohai Biological is 26.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
